Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Opening Session Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Jan
14
Today In Oncology
Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Multiple Myeloma Sex Differences in Etiology and Clinical Presentation
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive mCRPC
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo